Latest Insider Transactions at Mimedx Group, Inc. (MDXG)
This section provides a real-time view of insider transactions for Mimedx Group, Inc. (MDXG). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MIMEDX GROUP, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MIMEDX GROUP, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 08
2024
|
Rice Doug Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,749
-7.93%
|
$76,494
$6.79 P/Share
|
|
Jun 05
2024
|
Cato T Laurencin Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,190
+13.14%
|
$162,330
$7.26 P/Share
|
|
Jun 05
2024
|
Todd Newton Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,190
+5.69%
|
$162,330
$7.26 P/Share
|
|
Jun 05
2024
|
James L Bierman Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,190
+11.18%
|
$162,330
$7.26 P/Share
|
|
Jun 05
2024
|
Tiffany Olson Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,988
+50.0%
|
$202,916
$7.26 P/Share
|
|
Jun 05
2024
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,190
+11.68%
|
$162,330
$7.26 P/Share
|
|
Jun 05
2024
|
M Kathleen Behrens Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,190
+11.18%
|
$162,330
$7.26 P/Share
|
|
Jun 05
2024
|
Dorothy E Puhy Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,988
+50.0%
|
$202,916
$7.26 P/Share
|
|
May 08
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.92%
|
$62,272
$7.2 P/Share
|
|
Apr 23
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.89%
|
$53,376
$6.51 P/Share
|
|
Apr 08
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,896
-1.85%
|
$53,376
$6.9 P/Share
|
|
Mar 13
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Open market or private sale
|
Direct |
20,381
-4.07%
|
$142,667
$7.95 P/Share
|
|
Mar 04
2024
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,351
-2.98%
|
$122,808
$8.26 P/Share
|
|
Mar 01
2024
|
Rice Doug Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,478
+26.68%
|
-
|
|
Mar 01
2024
|
Ricci S Whitlow Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,478
+11.29%
|
-
|
|
Mar 01
2024
|
William Frank Iv Hulse General Counsel and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
59,127
+10.29%
|
-
|
|
Feb 20
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,271
-3.67%
|
$122,168
$8.01 P/Share
|
|
Feb 16
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,493
-3.59%
|
$123,944
$8.07 P/Share
|
|
Feb 15
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,198
-3.4%
|
$121,584
$8.06 P/Share
|
|
Feb 14
2024
|
Ricci S Whitlow Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
15,845
-3.42%
|
$126,760
$8.03 P/Share
|
|
Dec 22
2023
|
Falcon Fund 2 Holding Company, L.P. |
BUY
Conversion of derivative security
|
Direct |
28,195,249
+50.0%
|
-
|
|
Nov 21
2023
|
Rice Doug Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+4.66%
|
$35,000
$7.16 P/Share
|
|
Jul 05
2023
|
Rice Doug Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,200
+50.0%
|
-
|
|
Jun 23
2023
|
Joseph H Capper Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
42,025
+29.59%
|
$252,150
$6.5 P/Share
|
|
Jun 22
2023
|
Joseph H Capper Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
57,975
+50.0%
|
$347,850
$6.33 P/Share
|
|
Jun 13
2023
|
M Kathleen Behrens Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+18.01%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
James L Bierman Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+18.01%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
Phyllis Gardner Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+23.2%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
Cato T Laurencin Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+21.36%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
Todd Newton Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+8.92%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
William A Hawkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+18.85%
|
$141,416
$4.95 P/Share
|
|
Jun 13
2023
|
Michael J Giuliani Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,354
+21.36%
|
$141,416
$4.95 P/Share
|
|
May 16
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
10,365
-3.16%
|
$51,825
$5.95 P/Share
|
|
May 15
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
3,607
-1.09%
|
$21,642
$6.15 P/Share
|
|
May 10
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
5,869
-1.74%
|
$29,345
$5.93 P/Share
|
|
May 10
2023
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Open market or private sale
|
Direct |
5,870
-1.27%
|
$29,350
$5.93 P/Share
|
|
May 10
2023
|
Peter M Carlson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,976
-0.9%
|
$29,880
$5.93 P/Share
|
|
May 10
2023
|
William Lawrence Phelan Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,595
-0.86%
|
$7,975
$5.93 P/Share
|
|
May 04
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
51,756
-13.29%
|
$258,780
$5.34 P/Share
|
|
May 02
2023
|
William Lawrence Phelan Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,200
-2.72%
|
$15,600
$3.8 P/Share
|
|
Apr 25
2023
|
William Lawrence Phelan Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,628
-0.85%
|
$4,884
$3.74 P/Share
|
|
Apr 25
2023
|
Peter M Carlson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,094
-0.91%
|
$18,282
$3.74 P/Share
|
|
Apr 25
2023
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Open market or private sale
|
Direct |
5,988
-1.28%
|
$17,964
$3.74 P/Share
|
|
Apr 25
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
5,987
-1.51%
|
$17,961
$3.74 P/Share
|
|
Apr 11
2023
|
Robert Benjamin Stein President, Regenerative Med. |
SELL
Open market or private sale
|
Direct |
5,996
-1.49%
|
$17,988
$3.31 P/Share
|
|
Apr 11
2023
|
William Lawrence Phelan Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,632
-0.84%
|
$4,896
$3.31 P/Share
|
|
Apr 11
2023
|
Peter M Carlson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,100
-0.9%
|
$18,300
$3.31 P/Share
|
|
Apr 11
2023
|
William Frank Iv Hulse General Counsel and CAO |
SELL
Open market or private sale
|
Direct |
5,995
-1.26%
|
$17,985
$3.31 P/Share
|
|
Mar 13
2023
|
Robert Benjamin Stein President, Regenerative Med. |
BUY
Grant, award, or other acquisition
|
Direct |
135,065
+25.18%
|
$540,260
$4.62 P/Share
|
|
Mar 13
2023
|
Peter M Carlson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
140,455
+17.23%
|
$561,820
$4.62 P/Share
|